The DOI matches its Crossref record.
Combinations of Vancomycin and β-Lactams Are Synergistic against Staphylococci with Reduced Susceptibilities to Vancomycin
Open accessAbstract
Evidence of synergism between combinations of vancomycin and β-lactam antibiotics against 59 isolates of methicillin-resistant staphylococci ( Staphylococcus aureus , Staphylococcus epidermidis , and Staphylococcus haemolyticus ) for which vancomycin MICs ranged from 1 to 16 μg/ml were tested by broth microdilution checkerboard, disk diffusion, agar dilution, and time-kill antimicrobial susceptibility tests. The combination of vancomycin and oxacillin demonstrated synergy by all test methods against 30 of 59 isolates; no antagonism was seen. Synergy with vancomycin was also found by modified disk diffusion testing for ceftriaxone, ceftazidime, cefpodoxime, and amoxicillin-clavulanate but not for aztreonam. Evidence of synergy correlated directly with vancomycin MICs. The efficacy of vancomycin given alone and in combination with nafcillin was tested in the rabbit model of experimental endocarditis caused by three clinical isolates of glycopeptide-intermediate-susceptible S. aureus (GISA) (isolates HIP5827, HIP5836, and MU50). Two of the GISA isolates (isolates MU50 and HIP5836) were extremely virulent in this model, with 27 of 42 (64%) animals dying during the 3-day trial. Therapy with either vancomycin or nafcillin given as a single agent was ineffective for animals infected with HIP5827 or MU50. However, the combination of vancomycin and nafcillin resulted in a mean reduction of 4.52 log 10 CFU/g of aortic valvular vegetations per g compared to the reduction for controls for animals infected with HIP5827 and a reduction of 4.15 log 10 CFU/g for animals infected with MU50. Renal abscesses caused by HIP5827 were sterilized significantly better with the combination of vancomycin and nafcillin than by either treatment alone. We conclude that the combination of vancomycin and β-lactams with antistaphylococcal activity is an effective regimen for the treatment of infections with clinical strains of staphylococci which demonstrate reduced susceptibility to glycopeptides.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Cosgrove, S. E., Sakoulas, G., Perencevich, E. N., Schwaber, M. J., Karchmer, A. W., & Carmeli, Y. (2003) · Clinical Infectious Diseases · doi:10.1086/345476 · Cited by 1,964
Horstkotte, D. (2004) · European Heart Journal · doi:10.1016/j.ehj.2003.11.008 · Cited by 730
Increasing Resistance to Vancomycin and Other Glycopeptides in Staphylococcus aureus
Tenover, F. C., Biddle, J. W., & Lancaster, M. V. (2001) · Emerging Infectious Diseases · doi:10.3201/eid0702.010237 · Cited by 391
Fridkin, S. K., Hageman, J., McDougal, L. K., Mohammed, J., Jarvis, W. R., Perl, T. M., Tenover, F. C., & the Vancomycin‐Intermediate Staphylococcus aureus Epidemiology Study Group (2003) · Clinical Infectious Diseases · doi:10.1086/346207 · Cited by 344
Metadata
- Authors
- Climo, M. W., Patron, R. L., & Archer, G. L.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1999-07
- Volume
- 43
- Issue
- 7
- Pages
- 1747-1753
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2107074458
- Cited by
- 189
- References
- 0
- FWCI
- 7.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combinations of Vancomycin and β-Lactams Are Synergistic against Staphylococci with Reduced Susceptibilities to Vancomycin. https://app.cochat.ai/papers/10.1128/aac.43.7.1747
- The paper
- Climo, M. W., Patron, R. L., & Archer, G. L. (1999). Combinations of Vancomycin and β-Lactams Are Synergistic against Staphylococci with Reduced Susceptibilities to Vancomycin. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.43.7.1747
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.